Cargando…

Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation

Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The result...

Descripción completa

Detalles Bibliográficos
Autores principales: Swe, Hla Nu, Sritularak, Boonchoo, Rojnuckarin, Ponlapat, Luechapudiporn, Rataya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267677/
https://www.ncbi.nlm.nih.gov/pubmed/34202163
http://dx.doi.org/10.3390/ijms22136846
_version_ 1783720194149974016
author Swe, Hla Nu
Sritularak, Boonchoo
Rojnuckarin, Ponlapat
Luechapudiporn, Rataya
author_facet Swe, Hla Nu
Sritularak, Boonchoo
Rojnuckarin, Ponlapat
Luechapudiporn, Rataya
author_sort Swe, Hla Nu
collection PubMed
description Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The results indicated that lusianthridin inhibited arachidonic acid, collagen, and adenosine diphosphate (ADP)-stimulated platelet aggregation (IC(50) of 0.02 ± 0.001 mM, 0.14 ± 0.018 mM, and 0.22 ± 0.046 mM, respectively). Lusianthridin also increased the delaying time of arachidonic acid-stimulated and the lag time of collagen-stimulated and showed a more selective effect on the secondary wave of ADP-stimulated aggregations. Molecular docking studies revealed that lusianthridin bound to the entrance site of the cyclooxygenase-1 (COX-1) enzyme and probably the active region of the cyclooxygenase-2 (COX-2) enzyme. In addition, lusianthridin showed inhibitory effects on both COX-1 and COX-2 enzymatic activities (IC(50) value of 10.81 ± 1.12 µM and 0.17 ± 1.62 µM, respectively). Furthermore, lusianthridin significantly inhibited ADP-induced suppression of cAMP formation in platelets at 0.4 mM concentration (p < 0.05). These findings suggested that possible mechanisms of lusianthridin on the antiplatelet effects might act via arachidonic acid-thromboxane and adenylate cyclase pathways.
format Online
Article
Text
id pubmed-8267677
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82676772021-07-10 Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation Swe, Hla Nu Sritularak, Boonchoo Rojnuckarin, Ponlapat Luechapudiporn, Rataya Int J Mol Sci Article Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The results indicated that lusianthridin inhibited arachidonic acid, collagen, and adenosine diphosphate (ADP)-stimulated platelet aggregation (IC(50) of 0.02 ± 0.001 mM, 0.14 ± 0.018 mM, and 0.22 ± 0.046 mM, respectively). Lusianthridin also increased the delaying time of arachidonic acid-stimulated and the lag time of collagen-stimulated and showed a more selective effect on the secondary wave of ADP-stimulated aggregations. Molecular docking studies revealed that lusianthridin bound to the entrance site of the cyclooxygenase-1 (COX-1) enzyme and probably the active region of the cyclooxygenase-2 (COX-2) enzyme. In addition, lusianthridin showed inhibitory effects on both COX-1 and COX-2 enzymatic activities (IC(50) value of 10.81 ± 1.12 µM and 0.17 ± 1.62 µM, respectively). Furthermore, lusianthridin significantly inhibited ADP-induced suppression of cAMP formation in platelets at 0.4 mM concentration (p < 0.05). These findings suggested that possible mechanisms of lusianthridin on the antiplatelet effects might act via arachidonic acid-thromboxane and adenylate cyclase pathways. MDPI 2021-06-25 /pmc/articles/PMC8267677/ /pubmed/34202163 http://dx.doi.org/10.3390/ijms22136846 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Swe, Hla Nu
Sritularak, Boonchoo
Rojnuckarin, Ponlapat
Luechapudiporn, Rataya
Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title_full Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title_fullStr Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title_full_unstemmed Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title_short Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
title_sort inhibitory mechanisms of lusianthridin on human platelet aggregation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267677/
https://www.ncbi.nlm.nih.gov/pubmed/34202163
http://dx.doi.org/10.3390/ijms22136846
work_keys_str_mv AT swehlanu inhibitorymechanismsoflusianthridinonhumanplateletaggregation
AT sritularakboonchoo inhibitorymechanismsoflusianthridinonhumanplateletaggregation
AT rojnuckarinponlapat inhibitorymechanismsoflusianthridinonhumanplateletaggregation
AT luechapudipornrataya inhibitorymechanismsoflusianthridinonhumanplateletaggregation